{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T10:35:48Z","timestamp":1764326148517,"version":"3.46.0"},"reference-count":35,"publisher":"Wiley","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Deutsche Derma Gesell"],"abstract":"Summary<\/jats:title>\n \n Background and objectives<\/jats:title>\n Psoriasis can result in reduced quality of life, work productivity loss, and a significant restriction in non\u2010professional activities. This study investigates the effects of long\u2010term treatment with adalimumab regarding work ability, non\u2010professional activities, and health\u2010related quality of life in a large real\u2010word population in Germany.<\/jats:p>\n <\/jats:sec>\n \n Patients and methods<\/jats:title>\n Single\u2010arm, multicenter non\u2010interventional study to document routine care data for up to 5\u00a0years in adult patients with psoriasis after initiation of adalimumab.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Baseline data was collected for 4,793 (62.1 % male) patients with a mean (\u00b1 SD) age of 47.5 \u00b1 13.11\u00a0years. The number of days with restrictions in non\u2010professional activities was much higher than in professional activities. Under adalimumab, the psoriasis\u2010related number of days unfit for work and number of days with restrictions in non\u2010professional activities significantly decreased. Correlation analyses showed that psoriatic arthritis, disease severity (PASI >\u00a010), and impairment of quality of life (DLQI >\u00a010) are associated with restrictions in non\u2010professional activities. Health\u2010related quality of life improved over the observed time but remained reduced in patients with restrictions in non\u2010professional activities.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Long\u2010term treatment with adalimumab had a favorable impact on clinical outcomes, employment\u2010related aspects, practice of non\u2010professional activities, and health\u2010related quality of life in psoriasis patients.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/ddg.15949","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T10:31:13Z","timestamp":1764325873000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of adalimumab treatment on impairment of non\u2010professional activities in psoriasis patients"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8042-7885","authenticated-orcid":false,"given":"Georgios","family":"Kokolakis","sequence":"first","affiliation":[{"name":"Psoriasis Research and Treatment Centre Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin Corporate Member of Freie Universit\u00e4t Berlin and Humboldt\u2010Universit\u00e4t zu Berlin Berlin Germany"},{"name":"Department of Dermatology Venereology and Allergology Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin Corporate Member of Freie Universit\u00e4t Berlin and Humboldt\u2010Universit\u00e4t zu Berlin Berlin Germany"},{"name":"Interdisciplinary Group of Molecular Immunopathology Dermatology\/Medical Immunology Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin Corporate Member of Freie Universit\u00e4t Berlin and Humboldt\u2010Universit\u00e4t zu Berlin Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Philipp","sequence":"additional","affiliation":[{"name":"General Practice Dermatology Oranienburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Mosch","sequence":"additional","affiliation":[{"name":"AbbVie Pharmaceutical Trading (Shanghai) Co., Ltd. Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn","family":"Fritz","sequence":"additional","affiliation":[{"name":"AbbVie Deutschland GmbH & Co. KG Wiesbaden Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Sabat","sequence":"additional","affiliation":[{"name":"Psoriasis Research and Treatment Centre Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin Corporate Member of Freie Universit\u00e4t Berlin and Humboldt\u2010Universit\u00e4t zu Berlin Berlin Germany"},{"name":"Interdisciplinary Group of Molecular Immunopathology Dermatology\/Medical Immunology Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin Corporate Member of Freie Universit\u00e4t Berlin and Humboldt\u2010Universit\u00e4t zu Berlin Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL\u201023 and IL\u201017 pathway in psoriasis","volume":"397","author":"Ghoreschi K","year":"2021","journal-title":"Lancet"},{"key":"e_1_2_9_3_1","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.12788\/j.sder.2018.011","article-title":"Common and Not\u2010So\u2010Common Comorbidities of Psoriasis","volume":"37","author":"Menter MA","year":"2018","journal-title":"Semin Cutan Med Surg"},{"key":"e_1_2_9_4_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052935","article-title":"Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003\u20102011","volume":"7","author":"Armstrong AW","year":"2012","journal-title":"PLoS One"},{"key":"e_1_2_9_5_1","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1684\/ejd.2013.1969","article-title":"Influence of psoriasis on work","volume":"23","author":"Mattila K","year":"2013","journal-title":"Eur J Dermatol"},{"key":"e_1_2_9_6_1","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/1346-8138.16517","article-title":"Work productivity in real\u2010life employed patients with plaque psoriasis: Results from the ProLOGUE study","volume":"49","author":"Saeki H","year":"2022","journal-title":"J Dermatol"},{"key":"e_1_2_9_7_1","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/bjd\/ljac027","article-title":"The impact of hidradenitis suppurativa on professional life","volume":"188","author":"Schneider\u2010Burrus S","year":"2023","journal-title":"Br J Dermatol"},{"key":"e_1_2_9_8_1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12913-015-0752-0","article-title":"How much of the productivity losses among psoriasis patients are due to psoriasis","volume":"15","author":"Mustonen A","year":"2015","journal-title":"BMC Health Serv Res"},{"key":"e_1_2_9_9_1","first-page":"10","volume-title":"Gesundheitsberichterstattung des Bundes Heft 11 \u201cSchuppenflechte\u201d","author":"Traupe H","year":"2002"},{"key":"e_1_2_9_10_1","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1111\/j.1365-2133.2007.07881.x","article-title":"Psoriasis has a major secondary impact on the lives of family members and partners","volume":"156","author":"Eghlileb AM","year":"2007","journal-title":"Br J Dermatol"},{"key":"e_1_2_9_11_1","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/bjd.18798","article-title":"A multinational assessment of work\u2010related productivity loss and indirect costs from a survey of patients with psoriasis","volume":"183","author":"Villacorta R","year":"2020","journal-title":"Br J Dermatol"},{"key":"e_1_2_9_12_1","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1684\/ejd.2014.2282","article-title":"Perceived impact of psoriasis on leisure\u2010time activities","volume":"24","author":"Leino M","year":"2014","journal-title":"Eur J Dermatol"},{"key":"e_1_2_9_13_1","unstructured":"Health Promotion Glossary of Terms 2021.2021. Available from:https:\/\/iris.who.int\/bitstream\/handle\/10665\/350161\/9789240038349\u2010eng.pdf?sequence=1[Last accessed June 10 2025]."},{"key":"e_1_2_9_14_1","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1365-2133.2006.07405.x","article-title":"European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey","volume":"155","author":"Dubertret L","year":"2006","journal-title":"Br J Dermatol"},{"key":"e_1_2_9_15_1","unstructured":"Targets of Sustainable Development Goal 3.2023. Availabel from:https:\/\/www.who.int\/europe\/about\u2010us\/our\u2010work\/sustainable\u2010development\u2010goals\/targets\u2010of\u2010sustainable\u2010development\u2010goal\u20103[Last accessed June 10 2025]."},{"key":"e_1_2_9_16_1","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1111\/jdv.14926","article-title":"Long\u2010term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis","volume":"32","author":"Gniadecki R","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_9_17_1","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jaad.2010.12.005","article-title":"Long\u2010term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open\u2010label extension study for patients from REVEAL","volume":"66","author":"Gordon K","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_9_18_1","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3545","article-title":"Efficacy of Adalimumab for Nail Psoriasis During 24 Months of Continuous Therapy","volume":"100","author":"Kokolakis G","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_9_19_1","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.3390\/jpm11111083","article-title":"The Effect of TNF\u2010alpha Inhibitors on Nail Psoriasis and Psoriatic Arthritis\u2010Real\u2010World Data from Dermatology Practice","volume":"11","author":"Kokolakis G","year":"2021","journal-title":"J Pers Med"},{"key":"e_1_2_9_20_1","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial","volume":"58","author":"Menter A","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_9_21_1","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/j.jaad.2010.10.020","article-title":"The effects of adalimumab treatment and psoriasis severity on self\u2010reported work productivity and activity impairment for patients with moderate to severe psoriasis","volume":"66","author":"Kimball AB","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_9_22_1","article-title":"Low satisfaction with medical care among patients with hidradenitis suppurativa: A multicenter study","author":"Wolk K","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_9_23_1","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1384055","article-title":"Patient\u2010reported assessment of medical care for chronic inflammatory skin diseases: an enterprise\u2010based survey","volume":"11","author":"Wolk K","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"e_1_2_9_24_1","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/ced.12841","article-title":"Relationship between psoriasis severity, clinical symptoms, quality of life and work productivity among patients in the USA","volume":"41","author":"Korman NJ","year":"2016","journal-title":"Clin Exp Dermatol"},{"key":"e_1_2_9_25_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-027535","article-title":"Impact of psoriasis severity on patient\u2010reported clinical symptoms, health\u2010related quality of life and work productivity among US patients: real\u2010world data from the Corrona Psoriasis Registry","volume":"9","author":"Strober B","year":"2019","journal-title":"BMJ Open"},{"key":"e_1_2_9_26_1","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1007\/s10067-020-05038-y","article-title":"Sustained improvement in work outcomes in employed patients with rheumatoid arthritis during 2 years of adalimumab therapy: an observational cohort study","volume":"39","author":"Behrens F","year":"2020","journal-title":"Clin Rheumatol"},{"key":"e_1_2_9_27_1","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s12325-018-0866-y","article-title":"Real\u2010World Postmarketing Study of the Impact of Adalimumab Treatment on Work Productivity and Activity Impairment in Patients with Psoriatic Arthritis","volume":"36","author":"Nakagawa H","year":"2019","journal-title":"Adv Ther"},{"key":"e_1_2_9_28_1","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20949088","article-title":"Real\u2010world evidence of the impact of adalimumab on work productivity and sleep measures in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis","volume":"12","author":"Tektonidou MG","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"e_1_2_9_29_1","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v105.42767","article-title":"Real\u2010world Cost per Responder Among Different Classes of Biologics for the Treatment of Psoriasis","volume":"105","author":"Godding LTH","year":"2025","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_9_30_1","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.1000776","article-title":"The social value of a PASI 90 or PASI 100 response in patients with moderate\u2010to\u2010severe plaque psoriasis in Spain","volume":"11","author":"Maravilla\u2010Herrera P","year":"2023","journal-title":"Front Public Health"},{"key":"e_1_2_9_31_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2023.105534","article-title":"Impact of key manifestations of psoriatic arthritis on patient quality of life, functional status, and work productivity: Findings from a real\u2010world study in the United States and Europe","volume":"90","author":"Walsh JA","year":"2023","journal-title":"Joint Bone Spine"},{"key":"e_1_2_9_32_1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1136\/annrheumdis-2014-205198","article-title":"Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double\u2010blind randomised placebo\u2010controlled study","volume":"74","author":"Kavanaugh A","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_9_33_1","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/j.1468-3083.2010.03600.x","article-title":"Psoriasis: an epidemiological evaluation of disease burden in 590 patients","volume":"24","author":"Meyer N","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_9_34_1","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1007\/s11136-016-1321-7","article-title":"Health\u2010related quality of life in patients with psoriasis: a systematic review of the European literature","volume":"25","author":"Obradors M","year":"2016","journal-title":"Qual Life Res"},{"key":"e_1_2_9_35_1","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1046\/j.1087-0024.2003.09110.x","article-title":"Quality of life in patients with psoriasis: a systematic literature review","volume":"9","author":"Korte J","year":"2004","journal-title":"J Investig Dermatol Symp Proc"},{"key":"e_1_2_9_36_1","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/09546630701646172","article-title":"Impact of adalimumab treatment on patient\u2010reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis","volume":"18","author":"Revicki DA","year":"2007","journal-title":"J Dermatolog Treat"}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.15949","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T10:31:30Z","timestamp":1764325890000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ddg.15949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":35,"alternative-id":["10.1111\/ddg.15949"],"URL":"https:\/\/doi.org\/10.1111\/ddg.15949","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"value":"1610-0379","type":"print"},{"value":"1610-0387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"2025-04-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"ddg.15949"}}